ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Regorafenib 40 mg tablet for treating metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy.

Subsidy status

Regorafenib 40 mg tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 4 January 2022.

MAF assistance does not apply to any formulations or strengths of trifluridine/tipiracil.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.


Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer (Updated 19 December 2022) PES Treatments for metastatic colorectal cancer (Updated 19 December 2022)